We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App





Researchers Discover World’s First Human Antibody that Could Inhibit New Coronavirus (SARS-CoV-2)

By LabMedica International staff writers
Posted on 14 Mar 2020
Researchers have developed the world’s first human antibody that could inhibit the new coronavirus (SARS-CoV-2) and ‘offers potential for prevention and treatment of COVID-19’. More...
A team of 10 scientists from the University of Utrecht (Utrecht, the Netherlands), the Erasmus Medical Centre (Rotterdam, the Netherlands), and biotech company Harbor BioMed (Cambridge, MA, USA) have published their research online on BioRxiv where it is under peer review before being published by the prestigious journal Nature.

During their earlier work on developing antibodies against MERS, SARS and another Hong Kong coronavirus (OC-43), the researchers had found antibodies that cross-reacted with those three different viruses and kept them from infecting. The researchers had stored the untested antibodies that did not react with all the three mutations, but did with SARS1, in the refrigerator. After the SARS2 crisis broke out, they immediately tested whether the antibodies that reacted with SARS1 also responded to SARS2 and then found the antibody that has now been published.

The researchers are now making efforts to tie up with a pharmaceutical company that can produce the antibody on a large scale as a medicine. According to the researchers, the antibody offers potential for the development of a medicine as well as a diagnostic test that everyone can perform at home to easily confirm if they are infected or not. However, before it can be marketed, the antibody is currently being made to undergo rigorous development and tests for toxicological properties which should take a few more months.

Related Links:
University of Utrecht
Erasmus Medical Centre
Harbor BioMed



Gold Member
SARS-CoV-2 PCR Test
Macurra SARS-CoV-2 PCR Kit
Online QC Software
Acusera 24•7
New
Fully-auto Specific Protein (Nephelometry) Analyzer
PA240
New
Gold Member
Pre- Eclampsia Control
Acusera Pre-Eclampsia Control
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: The approach supports myocardial infarction diagnosis in resource-limited settings by reducing delays between clinical suspicion and biochemical confirmation (Image Credit: Adobe Stock)

Portable Troponin Assay Brings Heart Attack Diagnosis Closer to Patients

Timely confirmation of myocardial infarction often depends on laboratory testing that may not be immediately available at the point of care. This gap between clinical suspicion and definitive evidence... Read more

Molecular Diagnostics

view channel
Image: The two new tests are used with the LightCycler 480 and LightCycler PRO instruments (Photo courtesy of Roche)

New PCR Assays Expand Cyclospora Testing for Outbreak Surveillance

Cyclospora cayetanensis, a food- and waterborne intestinal parasite, can cause prolonged diarrhea, fatigue, and abdominal cramping, placing added strain on urgent care and emergency departments during outbreaks.... Read more

Immunology

view channel
Image: Graphical Abstract (Morgane Fournier et al., Cell (2026). DOI: 10.1016/j.cell.2026.04.013)

Study Reveals Immune Mechanism Driving Severe COVID-19 Progression

Severe COVID-19 has highlighted gaps in understanding of early antiviral responses, particularly why some patients deteriorate despite timely care. Type I interferons are central to host defense, yet their... Read more

Microbiology

view channel
Image: An innovative countywide program in Taiwan combines risk-based screening with decentralized community care to improve hepatitis C detection and treatment (Image Credit: iStock)

Precision Screening Helps Close Hepatitis C Diagnosis and Treatment Gaps

Hepatitis C remains a leading cause of cirrhosis and liver cancer, yet many infections go undiagnosed or untreated because health systems fail to reach those at greatest risk. Although highly effective... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.